Downers Grove, IL – Coventry recently announced the release of the third part of its 2017 Drug Trends Series, which is based on all calendar year transactions billed through its PBM Program, First Script, as well as transactions from medical bill review to reflect the total pharmacy experience for their client base.
This third piece in the series focuses on opioids and compound drugs. These two therapeutic classes are frequently discussed in workers’ comp as opioids are prescribed to treat pain associated with injuries and compounds have been growing in popularity with physician dispensers.
Items shared in this edition included aggregate opioid and compound information which includes all drugs; and it also breaks out the results for comparison into the managed and unmanaged views.
Key trends from this piece included:
- Aggregate prescription cost per claim, including both managed and unmanaged script usage, decreased 10.9%
- Opioid costs and utilization dropped significantly
- A 13.2% drop in utilization drove a 17.3% decrease in cost per claim.
- Opioids represented a smaller share of overall cost and utilization, declining 1.7% points and 1.4% point, respectively.
- Utilization of compound medications continued to fall, with unmanaged applications now at their lowest levels in 7 years.
View Part 3 here: Coventry 2017 First Script Drug Trends Report Series, Part 3 (PDF)
View Part 2 here: Coventry 2017 First Script Drug Trends Report Series, Part 2 (PDF)
View Part 1 here: Coventry 2017 First Script Drug Trends Report Series, Part 1 (PDF)
Coventry is a WorkCompWire ad partner.
This is not a paid placement.